3'-(cyclopentylsulfanyl)-1'-(1H-pyrazol-3-yl)-7'H-spiro[cyclobutane-1,6'-thieno[3,4-c]pyridine]-4'(5'H)-one | 1374102-83-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3'-(cyclopentylsulfanyl)-1'-(1H-pyrazol-3-yl)-7'H-spiro[cyclobutane-1,6'-thieno[3,4-c]pyridine]-4'(5'H)-one
• 英文别名: 3-cyclopentylsulfanyl-1-(1H-pyrazol-5-yl)spiro[5,7-dihydrothieno[3,4-c]pyridine-6,1'-cyclobutane]-4-one
• CAS: 1374102-83-6
• 化学式: C₁₈H₂₁N₃OS₂
• 分子量: 359.516
• InChiKey: UDPUKZMXDWNIOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] ACTIVITÉ DE L'ENZYME KINASE À RÉPÉTITION RICHE EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012058193A1

  公开（公告）日：2012-05-03

  Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein "A" is S-; -SO-, -SO2-, -O- or NRac-, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

  揭示了以下式（I）的化合物及其药用盐，其中“A”为S-；-SO-；-SO2-；-O-或NRac-，其中Rac为H或C1-20烷基，R1至R5在此处定义。还揭示了包括式I的化合物的药物配方，以及通过抑制LRRK2激酶活性治疗、管理或改善适用于治疗、管理或改善的疾病的方法，例如帕金森病。
• LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
  申请人：McCauley John A.

  公开号：US20130296317A1

  公开（公告）日：2013-11-07

  Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO 2 —, —O— or NR ac —, wherein Rac is H, or C 1-20 alkyl and R 1 through R 5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

  本发明涉及一种公式（I）的化合物及其药学上可接受的盐，其中“A”为S—；—SO—，—SO2—，—O或NRac—，其中Rac为H或C1-20烷基，R1至R5的定义如本文所述。本发明还涉及包含公式I化合物的药物配方以及通过抑制LRRK2激酶活性治疗、管理或改善可治疗、管理或改善的疾病的方法，例如帕金森病。
• FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd

  公开号：EP3653625A1

  公开（公告）日：2020-05-20

  The present inventon provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like; y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula: L1 is a single bond or the like; L2 is -C(=O)- or the like; L3 is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.

  本发明提供下式 (I) 所代表的化合物： 其中一个分子由式： 或类似物； y 是 0 或 1； R1 是氢或类似物； R2a 和 R2b 与相邻碳原子结合形成环 B； 环 B 是取代或未取代的非芳香族碳环或类似物； R3a 是氢或类似物； R3b 是氢或类似物； R4a 由式表示： L1 是单键或类似物；L2 是 -C(=O)- 或类似物；L3 是单键或类似物；R7 是取代或未取代的烷基或类似物；R4b 是取代或未取代的烷基或类似物；R4c 各自独立地是卤素或类似物。
• Fused ring derivative having MGAT-2 inhibitory activity
  申请人：Shionogi & Co., Ltd.

  公开号：US11198695B2

  公开（公告）日：2021-12-14

  The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

  本发明提供了下式 (I) 所代表的化合物： 其中由式 或类似符号。符号在说明书中定义。本发明的化合物具有 MGAT2 抑制活性，可作为治疗肥胖、代谢综合征、高脂血症、高甘油三酯血症、高 VLDL-三甘油三酯血症、高脂肪血症、糖尿病和动脉硬化等 MGAT2 相关疾病的药物。
• US9233977B2
  申请人：——

  公开号：US9233977B2

  公开（公告）日：2016-01-12